A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2018

At a glance

  • Drugs IONIS APOCIII LRx (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Akcea Therapeutics
  • Most Recent Events

    • 03 May 2018 According to a company media release, data will be preasented at the American College of Cardiology (ACC) Annual Scientific Session and Expo.
    • 05 Jan 2018 According to a company media release, Akcea anticipates reporting top-line data from this study in 2019.
    • 05 Jan 2018 Status changed from planning to recruiting according to an Akcea Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top